Introduction/Overview
Berberine, CAS number 15401-69-1, is an important natural alkaloid belonging to the berberine class of derivatives. As one of the main metabolites of berberine, berberine is widely present in traditional Chinese medicine, especially abundant in Berberis plants. In recent years, with the development of natural product pharmacology, berberine has received widespread attention due to its diverse biological activities and potential therapeutic value. Especially in the field of neurological diseases, such as migraine disorder, berberine exhibits unique pharmacological effects, and its mechanism of action involves multiple molecular targets, including ALOX15, BCHE, ACHE, EDNRA, DRD1, ADRA1A, TAAR1, EP300, and P2RX7.
This article provides a systematic review of the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action of berberine. Combined with drug evaluation and pharmacokinetic characteristics, it explores its clinical application prospects in neurological diseases such as migraine, aiming to provide theoretical basis and reference for the in-depth research and drug development of this natural product.
Chemical structure and physicochemical properties
The chemical name of berberine is 3,9-dihydroxy-2,3-dihydro-7,8-dimethoxy-5H-benzo [d] isoquinoline-5-one, with a molecular formula of C18H14NO4 and a molecular weight of 322.34. Its structure is a typical isoquinoline alkaloid skeleton, containing two hydroxyl and two methoxy substituents, giving it high polarity and a certain degree of hydrophilicity. The LogP value is 1.32, indicating that it has moderate lipid solubility, which is beneficial for cell membrane penetration, but has low blood-brain barrier permeability (BBB permeability is low), which poses certain challenges for the development of central nervous system drugs.
The topological polar surface area (TPSA) of berberine is 71.95 Å ², with 5 hydrogen bond acceptors, indicating its strong hydrogen bonding ability, which may affect its binding affinity with biomolecules. It has good chemical stability and is easily soluble in polar organic solvents such as methanol and ethanol, making it suitable for various extraction and separation techniques. There is no clear data on safety indicators such as hepatotoxicity, cardiotoxicity, hERG channel inhibition, and Ames mutagenicity, indicating that future research needs to focus on their safety assessment.
Plant sources and extraction methods
Berberine is mainly found in plants such as Berberis spp. and Coptis spp., especially in traditional Chinese medicinal herbs such as Coptis chinensis and Berberis vulgaris, where its content is relatively high. As an oxidative metabolite of berberine, it is usually generated through enzymatic reactions in plants or obtained through oxidative transformation during in vitro extraction.
The common methods for extracting berberine include:
-
Solvent extraction method Using methanol, ethanol, or a mixture of water and alcohol solvents to extract dried plant powder, combined with ultrasound assisted extraction or reflux extraction, to improve extraction efficiency.
-
Liquid-liquid distribution method Separate berberine from other alkaloids using solvent systems of different polarities, commonly using organic solvents such as chloroform and ethyl acetate.
-
Chromatographic separation technology Including silica gel column chromatography, reverse phase high performance liquid chromatography (RP-HPLC), and preparative HPLC, it can achieve the separation and purification of high-purity berberine.
-
Derivative and oxidation methods Some studies have used oxidants to convert berberine into berberine, simulating its in vivo metabolic process, in order to obtain sufficient pure products for pharmacological research.
In recent years, green extraction technologies such as supercritical CO ₂ extraction and microwave-assisted extraction have also been applied to the extraction of berberine, aiming to improve extraction efficiency and reduce the use of organic solvents, in line with the environmental protection requirements of modern natural product development.
Pharmacological activity research
Berberine, as a natural alkaloid product, exhibits various pharmacological activities, including anti-inflammatory, antioxidant, neuroprotective, and neurotransmitter regulation. Its therapeutic potential in neurological diseases is particularly noteworthy.
-
anti-inflammatory effect
Berberine can significantly inhibit the release of inflammatory mediators, reduce the expression of inflammatory factors such as TNF - α and IL-6, and alleviate inflammatory reactions. Its regulatory effect on lipoxygenase 15 (ALOX15) inhibits lipid mediated inflammatory cascade reactions, becoming an important component of its anti-inflammatory mechanism.
-
Neuroprotective effect
In the neurotoxic model, berberine exhibits the ability to protect neurons from oxidative stress and inflammatory damage. By regulating the activity of acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE), the balance of neurotransmitters is improved, and the recovery of neurological function is promoted.
-
Regulating the neurotransmitter system
Berberine has a regulatory effect on various neurotransmitter receptors, including dopamine D1 receptor (DRD1), alpha 1 adrenergic receptor (ADRA1A), and peptide receptor (TAAR1), by modulating neurotransmitter signaling and improving nervous system dysfunction.
-
Vascular regulatory effect
By acting on the endothelin receptor A (EDNRA), berberine can regulate vascular contraction and relaxation, improve cerebral hemodynamics, and help alleviate vascular neurological diseases such as migraine.
-
Immune regulatory effect
Berberine has a regulatory effect on the P2X7 receptor (P2RX7), affecting the activation and apoptosis of inflammatory cells, and participating in the regulation of immune responses.
In summary, the multi-target and multi pathway effects of berberine have laid a solid pharmacological foundation for its application in neurological diseases.
Mechanism of action and molecular targets
The mechanism of action of berberine in neurological disorders such as migraine is complex, involving the synergistic regulation of multiple molecular targets:
-
ALOX15 (Lipoxygenase 15)ALOX15 catalyzes the oxidation of fatty acids, producing various inflammatory mediators. Berberine reduces the production of inflammatory mediators and alleviates neuroinflammation by inhibiting ALOX15 activity.
-
BCHE (butyrylcholinesterase) and ACHE (acetylcholinesterase)These two enzymes regulate cholinergic neurotransmission. Berberine inhibits its activity, increases acetylcholine levels, and improves nerve conduction function.
-
EDNRA (endothelin receptor A)Mediating vasoconstriction, berberine antagonizes EDNRA, promotes vasodilation, improves cerebral blood flow, and alleviates migraine symptoms.
-
DRD1 (dopamine D1 receptor)The dopamine signaling pathway is involved in pain regulation, while berberine regulates DRD1 activity and affects pain perception in the central nervous system.
-
ADRA1A (alpha 1 adrenergic receptor)Participating in the regulation of the sympathetic nervous system, berberine regulates this receptor, affecting vascular tone and neural excitability.
-
TAAR1 (peptide receptor)Regulating neurotransmitter release and neuronal activity, berberine regulates nervous system homeostasis through TAAR1.
-
EP300 (Histone Acetyltransferase)As a transcription regulatory factor, EP300 is involved in gene expression regulation, and berberine may regulate neuronal function by affecting EP300.
-
P2RX7 (P2X7 receptor)Regulating inflammatory response and cell apoptosis, berberine regulates immune response and alleviates neuroinflammation through this receptor.
The comprehensive regulatory effect of these targets endows berberine with multidimensional therapeutic potential in migraine and related neurological disorders.
Evaluation of drug properties and pharmacokinetics
The pharmacological parameters of berberine show that it has certain potential for drug development, but there are also challenges:
-
Molecular weight (322.34)Complies with Lipinski's rules and is beneficial for oral absorption.
-
LogP（1.32）Moderate, with both hydrophilicity and lipophilicity, beneficial for in vivo distribution.
-
TPSA（71.95 Ų）Suitable for cell membrane penetration, but with low blood-brain barrier permeability, it may limit its direct action in the central nervous system.
-
Number of hydrogen bond acceptors (5)Moderate, affecting the binding and solubility of molecules and targets.
In terms of safety, there is still a lack of systematic research on key indicators such as hepatotoxicity, cardiotoxicity, hERG channel inhibition, and mutagenicity, which need to be evaluated in subsequent in vitro and in vivo toxicology studies.
In terms of pharmacokinetics, there is currently limited research on the absorption, distribution, metabolism, and excretion (ADME) of berberine. Preliminary data suggests that its oral bioavailability is limited and may decrease due to first pass effects and metabolic enzyme activity. Its metabolic pathway may involve the liver cytochrome P450 enzyme system, and the activity and safety of metabolites are yet to be clarified.
In the future, optimizing the pharmacokinetic properties of berberine through strategies such as structural modification and nanocarrier delivery may enhance its bioavailability and brain targeting ability.
Clinical application prospects and prospects
Berberine has shown promising application prospects in the treatment of neurological disorders such as migraine. Its multi-target regulatory effect helps alleviate the complex pathological mechanisms of migraine, including neuroinflammation, vascular dysfunction, and neurotransmitter imbalance.
Although berberine has not yet entered the clinical trial stage, its significant pharmacological activity and natural product safety advantages provide a good foundation for the development of new drugs. Future research should focus on:
-
Elucidation of the pharmacological mechanism of the system Especially its synergistic regulation of multiple targets in the nervous system and analysis of signaling pathways.
-
Safety and Toxicological Assessment This includes the liver and kidney toxicity, cardiovascular safety, and genetic toxicity of long-term medication.
-
Pharmacokinetic optimization Improve oral bioavailability and brain penetration ability, enhance therapeutic efficacy.
-
Preclinical animal model validation Evaluate its efficacy and safety in migraine and related neurological disorders.
-
Development of new dosage forms and routes of administration Such as sustained-release formulations, brain targeted nanocarriers, etc., to improve therapeutic efficacy.
Through interdisciplinary collaboration, combined with modern medicinal chemistry, molecular biology, and pharmacology techniques, berberine is expected to become a new candidate drug for the treatment of migraine and other neurological diseases.
Conclusion
Berberine, as a natural alkaloid with rich biological activity, has shown unique potential in the treatment of neurological diseases such as migraine due to its multi-target and multi pathway pharmacological effects. Its moderate physicochemical properties and natural product background provide a good foundation for drug development, but it also faces challenges such as poor blood-brain barrier permeability and insufficient safety data.
In the future, we should strengthen the systematic pharmacological mechanism research and safety evaluation of berberine, optimize its pharmacokinetic properties, and promote its transformation from laboratory research to clinical application. With the continuous advancement of natural product pharmacology and modern drug development technology, berberine is expected to become an important natural drug resource in the treatment of neurological diseases, bringing new treatment options for patients.
